Further US Lawsuit Claims Price-Fixing Conspiracy

Teva, along with Mylan, Pfizer, Sandoz and 16 other generics manufacturers, have found themselves in the spotlight after a further multi-state US lawsuit has accused them of participating in a price-fixing conspiracy.

Glasses
The latest lawsuit once again focuses on an alleged pricing conspiracy • Source: Shutterstock

A second multi-state lawsuit has been filed in the US as part of an ongoing and expanding investigation into generic drug pricing.

Teva, along with Mylan, Pfizer, Sandoz and 16 other generics manufacturers, have been named in a...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Drug Pricing

More from Policy & Regulation

  • For Generics, A Victory Lap – And A Warning – On Drug Shortages

    Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.

  • GB-Policy&Regulation-Free: Article with different widgets

    Emerging CRISPR innovations, shifting regulatory landscapes, and rising partnerships are accelerating a paradigm shift in biotech pipelines

  • Overseas API Manufacturing Identified As Key Vulnerability In US Supply Chain

    After US President Joe Biden launched a review of the country’s API supply chain, the task force has reported back with key vulnerabilities that contribute to drug shortages and supply risks during a global public health emergency. According to the report, the lack of geographic diversity and dependence on foreign nations and anti-competitive actions by foreign nations are key areas of concern.